Zhaoke Ophthalmology: Bringing Focus to China
Zhaoke Ophthalmology is a pre-revenue pharmaceutical company specializing in ophthalmic drugs for China that has filed to list on the HKEX. Lee's...
444 Views
Innovent Biologics Placement - Momentum Is Very Strong but past Deals Have Been Mixed
Innovent Biologics Inc (1801 HK) is looking to raise about U$600m to fund its clinical trials and product licensing and possible M&A. This will be...
429 Views
BeiGene: Novartis Grabs Tislelizumab Rights
BeiGene's deal with Novartis for PD-1 tislelizumab validates its competitive position, and marks a rising trend of Chinese companies licensing...
274 Views
Ocumension Theraputics Placement - IPO Was Hot, Deal Should Be Supported Despite Lock-Up Expiry
Ocumension Therapeutics (1477 HK) aims to raise around US$103m to commercialize new products, fund clinical trials and develop new facilities.
285 Views
Aequitas 2020 IPOs and Placements Performance - IPOs in the Limelight but Placements Stole the Show
2020 marked our second year of operations as an Independent Research Company, and our fifth year covering ECM. In 2020 we had an accuracy rate of...
418 Views